Page 1

PRESS RELEASE ● ● ● ● Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress AFM13 monotherapy : Reported positive outcome from the preplanned interim analysis for the registration - directed trial in PTCL ; enrollment expected to be completed in the first half of 2022 . affi med AFM13 combination with NK cells : Announced 100 % objective response rate in the first four response evaluable patients , including two complete responses . All three dose escalation cohorts are now fully enrolled ; data update expected in the second half of 2021 . AFM13 preclinical data : AFM13 in combination with natural killer ( NK ) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo . AFM24 monotherapy : AFM24 ( phase 1 / 2a study ) completed cohort 5 and is enrolling and treating patients in cohort 6 ; expansion cohorts expected to start in the second half of 2021 . AFM24 combination with NK cells : Combination therapy clinical trial of AFM24 with NKGen Biotech's SNK01 NK autologous cell therapy on track to start in the second half of 2021 . AFM24 combination with anti PD - L1 checkpoint inhibitor : Combination therapy clinical trial of AFM24 with atezolizumab ( Tecentriq® ) on track to start in the second half of 2021 . Cash and cash equivalents as of March 31 , 2021 , were approximately € 240.7 million with anticipated cash runway into the second half of 2023 . Conference call and webcast scheduled for July 1 , 2021 , at 8:30 a.m. EDT . Heidelberg , Germany , July 1 , 2021 – Affimed N.V. ( Nasdaq : AFMD ) , a clinical - stage immuno oncology company committed to giving patients back their innate ability to fight cancer , today reported financial results for the quarter ended March 31 , 2021 , and provided an update on clinical and corporate progress . " As we continue to build momentum with our clinical programs , we see growing interest in the important work that we are doing in the emerging field of innate immuno - oncology . We